Albireo Pharma - ALBO Competitors

EQRx (NASDAQ:EQRX) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends.

Which has preferable earnings & valuation, EQRX or ALBO?

Albireo Pharma has higher revenue and earnings than EQRx. Albireo Pharma is trading at a lower price-to-earnings ratio than EQRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EQRx	N/A	N/A	-$169.09 million	-$0.36	-5.00
Albireo Pharma	$40.58 million	22.52	-$34.03 million	-$6.72	-6.57

Does the media refer more to EQRX or ALBO?

In the previous week, EQRx had 1 more articles in the media than Albireo Pharma. MarketBeat recorded 2 mentions for EQRx and 1 mentions for Albireo Pharma. EQRx's average media sentiment score of 0.00 equaled Albireo Pharma's average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
EQRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Albireo Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is EQRX or ALBO more profitable?

EQRx has a net margin of 0.00% compared to Albireo Pharma's net margin of -228.51%. EQRx's return on equity of -18.43% beat Albireo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EQRx	N/A	-18.43%	-17.05%
Albireo Pharma	-228.51%	-97.13%	-46.89%

Does the MarketBeat Community prefer EQRX or ALBO?

Albireo Pharma received 293 more outperform votes than EQRx when rated by MarketBeat users. Likewise, 63.27% of users gave Albireo Pharma an outperform vote while only 50.00% of users gave EQRx an outperform vote.

Company	Underperform	Outperform
EQRx	Outperform Votes 5 50.00%	Underperform Votes 5 50.00%
Albireo Pharma	Outperform Votes 298 63.27%	Underperform Votes 173 36.73%

Which has more volatility and risk, EQRX or ALBO?

EQRx has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Do analysts recommend EQRX or ALBO?

EQRx presently has a consensus target price of $4.57, indicating a potential upside of 153.70%. Albireo Pharma has a consensus target price of $48.00, indicating a potential upside of 8.72%. Given EQRx's stronger consensus rating and higher possible upside, analysts plainly believe EQRx is more favorable than Albireo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EQRx	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Albireo Pharma	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14

Do insiders and institutionals hold more shares of EQRX or ALBO?

82.6% of EQRx shares are held by institutional investors. Comparatively, 94.3% of Albireo Pharma shares are held by institutional investors. 18.3% of EQRx shares are held by insiders. Comparatively, 6.9% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

EQRx beats Albireo Pharma on 10 of the 16 factors compared between the two stocks.